Seres Therapeutics (MCRB) Change in Account Payables (2014 - 2026)

Seres Therapeutics has reported Change in Account Payables for 13 years, with the latest figure at $656000.0 in Q1 2026.

• Quarterly Change in Account Payables rose 133.37% year-over-year to $656000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225000.0 (up 103.46% YoY) and the FY2025 annual result came in at -$2.4 million, up 18.47% from the prior year.
• Change in Account Payables grew to $656000.0 in Q1 2026 per MCRB's latest filing, from $5000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $7.2 million in Q2 2022 and troughed at -$6.5 million in Q1 2022.
• A 5-year average of -$826823.5 and a median of -$410000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 908.86% in 2022, then sank 1455.26% in 2025.
• Over 5 years, Change in Account Payables stood at $5.5 million in 2022, then plunged by 192.41% to -$5.0 million in 2023, then gained by 17.4% to -$4.2 million in 2024, then jumped by 100.12% to $5000.0 in 2025, then jumped by 13020.0% to $656000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $656000.0, $5000.0, and -$515000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.